Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):522-30. doi: 10.1089/cap.2012.0099. Epub 2013 Oct 10.

2.

Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance.

Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC.

BMC Pharmacol Toxicol. 2013 Aug 1;14:38. doi: 10.1186/2050-6511-14-38. Review.

3.

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia.

Pandina G, Kushner S, Karcher K, Haas M.

Child Adolesc Psychiatry Ment Health. 2012 Jun 7;6(1):23. doi: 10.1186/1753-2000-6-23.

4.
5.

Metabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: a retrospective cohort study.

Jerrell JM, McIntyre RS.

Prim Care Companion J Clin Psychiatry. 2010;12(4). pii: PCC.09m00891. doi: 10.4088/PCC.09m00891ora.

6.

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.

JAMA. 2009 Oct 28;302(16):1765-73. doi: 10.1001/jama.2009.1549. Erratum in: JAMA. 2009 Dec 2;302(21):2322.

Items per page

Supplemental Content

Write to the Help Desk